Disease overview

Alterations

110

Molecular (A)

100

Clinical (B–E)

Direct drugs

236

Via biomarker

191

Natural agents

Natural products

Merged ranked

425

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

CIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive cervical cancer: no spontaneous regression

Best-intervention remission

Early-stage (IA-IIA): radical hysterectomy or chemoradiation — 80-90% 5-year survival; locally advanced (IIB-IVA): cisplatin-based chemoradiation — 60-70% 5-year survival; metastatic with pembrolizumab + chemotherapy ± bevacizumab: 24.4 vs 16.3 months OS (KEYNOTE-826); ENGOT-cx11/GOG-3047: cemiplimab + chemo superior

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large from a prevention standpoint — HPV vaccination and screening can prevent most cervical cancers but coverage is dramatically insufficient

Primary barrier

access (prevention)

Barrier detail: HPV vaccination prevents ~90% of cervical cancers caused by HPV 16/18 (and gardasil 9 covers 9 types); cervical cancer screening (Pap + HPV co-testing) prevents invasive cancer; yet globally only 10% of women in LMICs have received the HPV vaccine; in the US, HPV vaccination coverage remains at ~60% of adolescents

Last SoC change: 2022 — cemiplimab approved as first-line for PD-L1+ advanced/metastatic CC; 2021 pembrolizumab as first-line (KEYNOTE-826); tisotumab vedotin (ADC) 2021; cisplatin chemoradiation as standard since 1999

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0002974

Alterations

Showing 80 of 110 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Cervix cancer	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ALK ALK receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID2 AT-rich interaction domain 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BAP1 BRCA1 associated deubiquitinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRCA2 BRCA2 DNA repair associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP8 caspase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD274 CD274 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK12 cyclin dependent kinase 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CFAP54 cilia and flagella associated protein 54	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLPTM1L CLPTM1 like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRTC1 CREB regulated transcription coactivator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNNB1 catenin beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change in health-related quality of life (EORTC QLQ-C30) from baseline to follow up	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Correlation of Overall Tumor Metabolic Response as Assessed by FDG-PET/CT With the Anatomic Tumor Response Rate by RECIST Criteria as Assessed by CT and Clinical Examination	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DCC DCC netrin 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DICER1 dicer 1, ribonuclease III	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EGFR epidermal growth factor receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EP300 EP300 lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB2 erb-b2 receptor tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERBB4 erb-b2 receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
F3 coagulation factor III, tissue factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAT1 FAT atypical cadherin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXO11 F-box protein 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXW7 F-box and WD repeat domain containing 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR2 fibroblast growth factor receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR3 fibroblast growth factor receptor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLT3 fms related receptor tyrosine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLT4 fms related receptor tyrosine kinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FMN2 formin 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HRAS HRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDM6A lysine demethylase 6A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDR kinase insert domain receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2C lysine methyltransferase 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2D lysine methyltransferase 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LATS1 large tumor suppressor kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRP1B LDL receptor related protein 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAML2 mastermind like transcriptional coactivator 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAPK1 mitogen-activated protein kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MSH2 mutS homolog 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MTOR mechanistic target of rapamycin kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYC MYC proto-oncogene, bHLH transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFE2L2 NFE2 like bZIP transcription factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOS1 nitric oxide synthase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH1 notch receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Overall survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PAX8 paired box 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDCD1 programmed cell death 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRA platelet derived growth factor receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDGFRB platelet derived growth factor receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA1 DNA polymerase alpha 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA2 DNA polymerase alpha 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD1 DNA polymerase delta 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD2 DNA polymerase delta 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD3 DNA polymerase delta 3, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD4 DNA polymerase delta 4, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE DNA polymerase epsilon, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE2 DNA polymerase epsilon 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLE3 DNA polymerase epsilon 3, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POT1 protection of telomeres 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POU5F1B POU class 5 homeobox 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRIM1 DNA primase subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRIM2 DNA primase subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PTEN phosphatase and tensin homolog	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Progression-free survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Quality of life using European Organisation for Research and Treatment of Cancer (EORTC) questionnaire	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
RB1 RB transcriptional corepressor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM1 ribonucleotide reductase catalytic subunit M1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM2 ribonucleotide reductase regulatory subunit M2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RRM2B ribonucleotide reductase regulatory TP53 inducible subunit M2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SETD2 SET domain containing 2, histone lysine methyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMAD2 SMAD family member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
METHAZOLAMIDE	Small molecule	Approved	Strong	100	1 trials View evidence Registry trials NCT00257829 — Improving Tumor Oxygenation in Cervical Cancer (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
NICOTINE	Small molecule	Approved	Strong	100	8 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT01434342 — Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients (COMPLETED) EARLY_PHASE1 NCT01084733 — Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer (COMPLETED) NCT00957424 — Acceptability of Less Harmful Alternatives to Cigarettes (COMPLETED) NA NCT06995417 — Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational Study (NOT_YET_RECRUITING) NCT06716892 — Non-invasive Preoperative Tissue Evaluation in Head and Neck Tumor Patients Using Multispectral Optoacoustic Tomography (MSOT) (RECRUITING) NCT06910566 — Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy (ACTIVE_NOT_RECRUITING) NCT00931021 — Smoking Cessation Treatment for Head and Neck Cancer Patients (TERMINATED) EARLY_PHASE1 NCT02840071 — ACT for Distress in Head and Neck Cancer Patients (UNKNOWN) NA Published literature Clinical trial publication Smoking Cessation by Cancer Treatment Status Among Cervical Cancer Survivors (American journal of preventive medicine, 2024) Clinical trial publication Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT02537223 — Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer (COMPLETED) PHASE1 NCT03601507 — Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer (TERMINATED) PHASE2 NCT06145308 — Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (RECRUITING) PHASE2 NCT04997902 — Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (COMPLETED) PHASE1, PHASE2 NCT05768139 — First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (RECRUITING) PHASE1, PHASE2 NCT06993844 — Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors (RECRUITING) PHASE1, PHASE2 NCT03138070 — A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 (COMPLETED) NA NCT02282371 — Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	8 trials 3 Cochrane 2 Meta-analysis 11 Trial pubs 6 RCT View evidence Registry trials NCT05395052 — FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (TERMINATED) PHASE1 NCT03181100 — Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT04939480 — Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (COMPLETED) PHASE2 NCT02914470 — Carboplatin-cyclophosphamide Combined With Atezolizumab (COMPLETED) PHASE1 NCT06254911 — Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma (SUSPENDED) PHASE2 NCT03841110 — FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (COMPLETED) PHASE1 NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers (RECRUITING) PHASE2 NCT04954599 — Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Efficacy and safety of immune checkpoint inhibitors combined with chemoradiotherapy in locally advanced cervical cancer: a systematic review and meta-analysis (Frontiers in pharmacology, 2026) Cochrane review Immune checkpoint therapy in locally advanced, persistent, recurrent, and metastatic cervical cancer: A systematic review and Bayesian network meta-analysis (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026) Cochrane review Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis (Frontiers in oncology, 2021) Meta-analysis Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy (Frontiers in immunology, 2026) Clinical trial publication Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer (Brachytherapy, 2026) Clinical trial publication Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc (Journal of gynecologic oncology, 2025) Clinical trial publication Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study (International journal of radiation oncology, biology, physics, 2026) Clinical trial publication Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial (Nature communications, 2025) Clinical trial publication Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study (Journal for immunotherapy of cancer, 2025) Randomized controlled trial A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2024) Randomized controlled trial Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial (Lancet (London, England), 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT04061980 — Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT05355701 — A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (RECRUITING) PHASE1 NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRENTUXIMAB VEDOTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABOZANTINIB S-MALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CEMIPLIMAB Repurposing	Small molecule	Approved	Strong	95	8 trials 8 Trial pubs 4 RCT View evidence Registry trials NCT05878288 — Deep sequencIng in Cutaneous Squamous CEll caRciNomas (ACTIVE_NOT_RECRUITING) PHASE2 NCT04954599 — Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (RECRUITING) PHASE1, PHASE2 NCT05535023 — Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma (WITHDRAWN) PHASE2 NCT03669718 — A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC (UNKNOWN) PHASE2 NCT06052852 — Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies (TERMINATED) PHASE1 NCT03198130 — An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (COMPLETED) PHASE1 NCT05929664 — Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (SUSPENDED) PHASE2 NCT03916627 — Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (ACTIVE_NOT_RECRUITING) PHASE2 Published literature Systematic review Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review (Frontiers in health services, 2025) Clinical trial publication Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial (Gynecologic oncology, 2025) Clinical trial publication Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial (European journal of cancer (Oxford, England : 1990), 2025) Clinical trial publication Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer (Cancer medicine, 2024) Clinical trial publication Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer (CPT: pharmacometrics & systems pharmacology, 2022) Clinical trial publication EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer (European journal of cancer (Oxford, England : 1990), 2022) Randomized controlled trial Survival with Cemiplimab in Recurrent Cervical Cancer (The New England journal of medicine, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
CERITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
COSIBELIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT05182931 — A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (UNKNOWN) PHASE2 NCT01723202 — Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer (COMPLETED) PHASE2 NCT04619316 — Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (UNKNOWN) PHASE2 NCT07010393 — Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study (NOT_YET_RECRUITING) PHASE4 NCT01947023 — Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery (ACTIVE_NOT_RECRUITING) PHASE1 NCT04238624 — Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT04554680 — Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy (UNKNOWN) PHASE2 NCT04544111 — PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
DABRAFENIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DENOSUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIPYRIDAMOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
ADEBRELIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BALSTILIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BLEOMYCIN SULFATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BULUMTATUG FUVEDOTIN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CADONILIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CAMRELIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CARBOPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CISPLATIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DOCETAXEL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DURVALUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ENLONSTOBART	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FAMITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FLUOROURACIL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GEMCITABINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HYDRALAZINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IFOSFAMIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IRINOTECAN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LORNOXICAM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MAGNESIUM VALPROATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
MITOMYCIN	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NIMOTUZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PACLITAXEL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PEMETREXED	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PLATINUM	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
PROLGOLIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RETLIRAFUSP ALFA	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SACITUZUMAB TIRUMOTECAN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SERPLULIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SOCAZOLIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TIRAPAZAMINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TOPOTECAN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TORIPALIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TRIAPINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VALPROIC ACID	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VINBLASTINE SULFATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VINCRISTINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VINDESINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABEMACICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB HYDROCHLORIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALPELISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT02537223 — Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer (COMPLETED) PHASE1 NCT03601507 — Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer (TERMINATED) PHASE2 NCT06145308 — Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (RECRUITING) PHASE2 NCT04997902 — Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (COMPLETED) PHASE1, PHASE2 NCT05768139 — First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (RECRUITING) PHASE1, PHASE2 NCT06993844 — Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors (RECRUITING) PHASE1, PHASE2 NCT03138070 — A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 (COMPLETED) NA NCT02282371 — Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
AMPHETAMINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	8 trials 3 Cochrane 2 Meta-analysis 11 Trial pubs 6 RCT View evidence Registry trials NCT05395052 — FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (TERMINATED) PHASE1 NCT03181100 — Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT04939480 — Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (COMPLETED) PHASE2 NCT02914470 — Carboplatin-cyclophosphamide Combined With Atezolizumab (COMPLETED) PHASE1 NCT06254911 — Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma (SUSPENDED) PHASE2 NCT03841110 — FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (COMPLETED) PHASE1 NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers (RECRUITING) PHASE2 NCT04954599 — Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (RECRUITING) PHASE1, PHASE2 Published literature Cochrane review Efficacy and safety of immune checkpoint inhibitors combined with chemoradiotherapy in locally advanced cervical cancer: a systematic review and meta-analysis (Frontiers in pharmacology, 2026) Cochrane review Immune checkpoint therapy in locally advanced, persistent, recurrent, and metastatic cervical cancer: A systematic review and Bayesian network meta-analysis (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026) Cochrane review Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis (Frontiers in oncology, 2021) Meta-analysis Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy (Frontiers in immunology, 2026) Clinical trial publication Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer (Brachytherapy, 2026) Clinical trial publication Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc (Journal of gynecologic oncology, 2025) Clinical trial publication Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study (International journal of radiation oncology, biology, physics, 2026) Clinical trial publication Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial (Nature communications, 2025) Clinical trial publication Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study (Journal for immunotherapy of cancer, 2025) Randomized controlled trial A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2024) Randomized controlled trial Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial (Lancet (London, England), 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
AVELUMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BEVACIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	3 trials View evidence Registry trials NCT04061980 — Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT05355701 — A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (RECRUITING) PHASE1 NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
BOSUTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BRENTUXIMAB VEDOTIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIGATINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CABOZANTINIB S-MALATE Repurposing via CTNNB1	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBAMAZEPINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
CELECOXIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CEMIPLIMAB Repurposing via CDK12	Small molecule	Approved	Strong	95	8 trials 8 Trial pubs 4 RCT View evidence Registry trials NCT05878288 — Deep sequencIng in Cutaneous Squamous CEll caRciNomas (ACTIVE_NOT_RECRUITING) PHASE2 NCT04954599 — Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (RECRUITING) PHASE1, PHASE2 NCT05535023 — Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma (WITHDRAWN) PHASE2 NCT03669718 — A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC (UNKNOWN) PHASE2 NCT06052852 — Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies (TERMINATED) PHASE1 NCT03198130 — An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (COMPLETED) PHASE1 NCT05929664 — Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (SUSPENDED) PHASE2 NCT03916627 — Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (ACTIVE_NOT_RECRUITING) PHASE2 Published literature Systematic review Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review (Frontiers in health services, 2025) Clinical trial publication Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial (Gynecologic oncology, 2025) Clinical trial publication Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial (European journal of cancer (Oxford, England : 1990), 2025) Clinical trial publication Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer (Cancer medicine, 2024) Clinical trial publication Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer (CPT: pharmacometrics & systems pharmacology, 2022) Clinical trial publication EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer (European journal of cancer (Oxford, England : 1990), 2022) Randomized controlled trial Survival with Cemiplimab in Recurrent Cervical Cancer (The New England journal of medicine, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
CERITINIB Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
CETUXIMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
COSIBELIMAB Repurposing via CD274	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing via CTNNB1	Small molecule	Approved	Strong	95	—	DGIdb	—
CYTARABINE Repurposing via ALK	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT05182931 — A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (UNKNOWN) PHASE2 NCT01723202 — Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer (COMPLETED) PHASE2 NCT04619316 — Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (UNKNOWN) PHASE2 NCT07010393 — Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study (NOT_YET_RECRUITING) PHASE4 NCT01947023 — Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery (ACTIVE_NOT_RECRUITING) PHASE1 NCT04238624 — Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 NCT04554680 — Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy (UNKNOWN) PHASE2 NCT04544111 — PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
DABRAFENIB MESYLATE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets

Natural Products

77 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin B12 Natural product Human Study A case-control nutrigenomic study on the synergistic activity of folate… Human Study Folate, riboflavin, thiamin and vitamin b12 protect against premalignan… Human Study Higher serum concentrations of folate and vitamin B12 are significantly…	Nutraceutical	Phase II	Emerging	10	8 trials View evidence Registry trials NCT03778008 — Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis (UNKNOWN) PHASE2 NCT00589667 — A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) (COMPLETED) PHASE2 NCT05625308 — Effect of Natural Compounds on the Severity of HPV-induced Cervical Lesions (COMPLETED) NA NCT01806272 — Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis (UNKNOWN) PHASE2 NCT02735317 — Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT (UNKNOWN) PHASE2 NCT00630149 — Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy (COMPLETED) PHASE2 NCT03903952 — Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS? (COMPLETED) NA NCT06979180 — A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (RECRUITING) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin C Natural product Human Study These findings indicated that antioxidant vitamins might be beneficial… Meta Analysis Dietary supplements reduce the risk of cervical intraepithelial neoplas… Meta Analysis Review: there is a consistently strong inverse correlations with solar…	Nutraceutical	Approved	Emerging	10	6 trials View evidence Registry trials NCT01953107 — Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. (COMPLETED) PHASE4 NCT00486304 — Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy (COMPLETED) PHASE1 NCT00284427 — Safety of Antioxidants During GYN Cancer Care (COMPLETED) PHASE2 NCT03531190 — Pre- and Postoperative Nutrition in Head and Neck Cancer Patients (COMPLETED) NA NCT06979180 — A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (RECRUITING) NA NCT02868151 — Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers (COMPLETED) PHASE2, PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Ginger Natural product Clinical trial publication Effect of Zingiber Officinale in the Management of Nausea and Vomiting… Clinical trial publication Use of ginger to control nausea and vomiting caused by chemotherapy in… Animal Study, In Vitro Study 6-Gingerol is a potent inducer of p53 reactivation in HPV positive cerv…	Botanical	Preclinical	Emerging	10	1 trials 2 Trial pubs View evidence Registry trials NCT05872464 — Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia (UNKNOWN) NA Published literature Clinical trial publication Effect of Zingiber Officinale in the Management of Nausea and Vomiting Induced by Treatment With Cisplatin Associated With Radiotherapy: A Randomized Controlled Trial (Integrative cancer therapies, 2023) Clinical trial publication Use of ginger to control nausea and vomiting caused by chemotherapy in patients with cervical cancer undergoing treatment: An experiment (Medicine, 2022) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin E Natural product Clinical trial publication Hyaluronic acid and vitamins are effective in reducing vaginal atrophy… Clinical trial publication [Significance of vitamins A and E in the cervical intraepithelial neopi… Clinical trial publication [Effect of antioxidant supplementation over oxidative stress and qualit…	Nutraceutical	Phase III	Emerging	10	8 trials 6 Trial pubs View evidence Registry trials NCT02397486 — The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients (COMPLETED) PHASE2 NCT00054561 — Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer (COMPLETED) PHASE3 NCT00486304 — Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy (COMPLETED) PHASE1 NCT06055257 — Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible (RECRUITING) PHASE3 NCT06979180 — A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (RECRUITING) NA NCT07668284 — COQ10 and Vitamin E for Off-Target Radiation Toxicity (NOT_YET_RECRUITING) PHASE1, PHASE2 NCT00169845 — Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients (COMPLETED) PHASE3 NCT06912763 — Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) (RECRUITING) PHASE2 Published literature Clinical trial publication Hyaluronic acid and vitamins are effective in reducing vaginal atrophy in women receiving radiotherapy (Minerva ginecologica, 2015) Clinical trial publication [Significance of vitamins A and E in the cervical intraepithelial neopiasia--CEN] (Przeglad lekarski, 2014) Clinical trial publication [Effect of antioxidant supplementation over oxidative stress and quality of life in cervical cancer] (Nutricion hospitalaria, 2011) Clinical trial publication beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1996) Clinical trial publication Effect of radiotherapy and chemoradiotherapy on circulating antioxidant system of human uterine cervical carcinoma (Molecular and cellular biochemistry, 1996) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Folate Natural product Human Study A case-control nutrigenomic study on the synergistic activity of folate… Human Study Folate, riboflavin, thiamin and vitamin b12 protect against premalignan… Meta Analysis Deficiency of serum folate level was associated with the increased risk…	Nutraceutical	Phase III	Emerging	10	8 trials 2 Cochrane 6 Meta-analysis 2 RCT View evidence Registry trials NCT00390416 — Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma (COMPLETED) PHASE2 NCT07039526 — Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. (RECRUITING) PHASE2 NCT03777813 — Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (COMPLETED) PHASE2 NCT00703196 — Folic Acid Clinical Trial for the Prevention of Cervical Cancer (COMPLETED) PHASE2 NCT06780111 — Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (RECRUITING) PHASE1, PHASE2 NCT06501664 — Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC (NOT_YET_RECRUITING) PHASE3 NCT02037048 — FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (UNKNOWN) PHASE2 NCT00154700 — Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Garlic Natural product Animal Study Garlic prevents methylcholanthrene-induced carcinogensis in the uterine… In Vitro Study Allicin inhibits the biological activities of cervical cancer cells by… In Vitro Study Allicin suppresses the migration and invasion in cervical cancer cells…	Food compound	Preclinical	Emerging	10	11 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Calcium Natural product Cochrane review The influence of nutrition on HPV-associated inflammation: a systematic… Meta Analysis Dietary supplements reduce the risk of cervical intraepithelial neoplas…	Nutraceutical	Phase III	Emerging	10	8 trials 1 Cochrane View evidence Registry trials NCT04085120 — Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain (UNKNOWN) NA NCT04432597 — HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (ACTIVE_NOT_RECRUITING) PHASE1, PHASE2 NCT04969926 — Natural History Study of Parathyroid Disorders (RECRUITING) NCT00697619 — To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer (COMPLETED) PHASE2 NCT00895245 — Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (TERMINATED) PHASE2 NCT06501664 — Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC (NOT_YET_RECRUITING) PHASE3 NCT02037048 — FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (UNKNOWN) PHASE2 NCT00004164 — Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx (UNKNOWN) PHASE2 Published literature Cochrane review The influence of nutrition on HPV-associated inflammation: a systematic review and meta-analysis (Frontiers in nutrition, 2025) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin D3 Natural product Meta Analysis Review: there is a consistently strong inverse correlations with solar… Meta Analysis Dietary supplements reduce the risk of cervical intraepithelial neoplas… Human Study A case-control nutrigenomic study on the synergistic activity of folate…	Nutraceutical	Phase III	Emerging	10	8 trials View evidence Registry trials NCT00697619 — To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer (COMPLETED) PHASE2 NCT05817617 — Vitamin D and Head and Neck Cancer: Impact on Toxicity and Prognosis (RECRUITING) NCT07042711 — Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients (ACTIVE_NOT_RECRUITING) NA NCT03484416 — Routine Calcium for Preventing Hypocalcemia (COMPLETED) NA NCT05568641 — Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma (UNKNOWN) NCT05252884 — Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial (COMPLETED) NA NCT06706401 — Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma (RECRUITING) PHASE3 NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Magnesium Natural product Human Study Magnesium was found to provide nephroprotective effects among patients… Human Study Cisplatin could produce magnesium deficiency in patients undergoing che…	Nutraceutical	Phase III	Emerging	10	8 trials 4 Trial pubs View evidence Registry trials NCT01837446 — Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer (COMPLETED) PHASE2, PHASE3 NCT02446652 — Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer (WITHDRAWN) PHASE3 NCT02018276 — Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery (COMPLETED) NA NCT05586009 — Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients (COMPLETED) PHASE2 NCT05121948 — A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (TERMINATED) PHASE1 NCT02826746 — Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy (COMPLETED) NA NCT07485296 — Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) (RECRUITING) PHASE2 NCT01035580 — Trial on Safety and Pharmacokinetics of Intravaginal Curcumin (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Curcumin Natural product Cochrane review Nanocurcumin in cancer treatment: a comprehensive systematic review Animal Study "A Novel Curcumin-based Vaginal Cream Vacurin Selectively Eliminat… Animal Study Combinational treatment effect of tetrahydrocurcumin and celecoxib on c…	Food compound	Phase III	Emerging	7	8 trials 1 Cochrane 2 Trial pubs View evidence Registry trials NCT04208334 — The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer (COMPLETED) PHASE2 NCT05856500 — A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors (UNKNOWN) NA NCT02554344 — Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) (WITHDRAWN) EARLY_PHASE1 NCT05947513 — Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial (RECRUITING) NA NCT01035580 — Trial on Safety and Pharmacokinetics of Intravaginal Curcumin (COMPLETED) PHASE1 NCT05982197 — Curcumin Gel On Radiation Induced Oral Mucositis (COMPLETED) NA NCT06080841 — Curcumin Supplementation in Cervical Cancer (RECRUITING) NA NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 Published literature Cochrane review Nanocurcumin in cancer treatment: a comprehensive systematic review (Discover oncology, 2024) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product In Vitro Study Berberine inhibits cancer cells growth by suppressing fatty acid synthe…	Botanical	Preclinical	Emerging	7	25 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Selenium Natural product Meta-analysis Serum Selenium Levels and Cervical Cancer: Systematic Review and Meta-A… Human Study Selenium supplementation during radiotherapy is effective in improving… Animal Study Cur/Se nanoparticles could increase the bioactivity of curcumin and imp…	Nutraceutical	Approved	Emerging	7	6 trials 1 Cochrane 1 Meta-analysis 2 RCT View evidence Registry trials NCT04683575 — Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma (UNKNOWN) PHASE4 NCT06736015 — Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a) (RECRUITING) NA NCT05451576 — Sodium Selenite Supplementation in Patients With Head and Neck Cancer (UNKNOWN) NA NCT01682031 — Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (TERMINATED) PHASE2 NCT06979180 — A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (RECRUITING) NA NCT06665841 — Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes (NOT_YET_RECRUITING) Published literature Meta-analysis Serum Selenium Levels and Cervical Cancer: Systematic Review and Meta-Analysis (Biological trace element research, 2017) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Black Seed Oil Natural product Animal Study Bee venom and thymoquinone combination inhibits cancer cells by inducin… Thymoquinone exhibits anti-proliferative, apoptotic and anti-invasive p… In Vitro Study A natural glucan from black bean inhibits cancer cell proliferation.	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Animal Study, In Vitro Study Gossypol reduces metastasis and epithelial-mesenchymal transition by ta… Transgenic Animal Study Indole-3 carbinol prevents human papilloma virus induced cervical cance… Animal Study, In Vitro Study Resveratrol and pterostilbene can serve as potential antineoplastic age…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Quercetin Natural product In Vitro Study Adlay seed ethanolic extract fractions and subfractions induce cell cyc…	Food compound	Phase II	Emerging	7	2 trials View evidence Registry trials NCT05456022 — Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line (UNKNOWN) PHASE2 NCT05724329 — Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Probiotics Natural product Human Study Probiotic use concomitantly with specific anti-infective agents provide… Human Study Supplementation of probiotic is an effective way to reduce the incidenc…	Probiotic	Phase III	Emerging	7	8 trials 6 Trial pubs View evidence Registry trials NCT02575313 — The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer (TERMINATED) PHASE1, PHASE2 NCT03574051 — the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism (UNKNOWN) EARLY_PHASE1 NCT07635277 — Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury (RECRUITING) PHASE1 NCT06122636 — Efficacy of a Probiotic and Microbiological Analysis on Oral Complications in Patients With HNC (COMPLETED) NA NCT05707702 — Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia (WITHDRAWN) PHASE3 NCT04871412 — The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (RECRUITING) PHASE3 NCT05736315 — Use of a Fermented Dairy Beverage in Cervical Cancer Patients Undergoing Concurrent Chemoradiation Therapy (COMPLETED) NA NCT03720015 — Concurrent Training and Nutritional Management in Cancer (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Reishi Natural product Animal Study Antitumor activity of enzymatically hydrolyzed Ganoderma lucidum polysa… Animal Study, In Vitro Study Chaga mushroom and its compounds could be used as natural anticancer in… Animal Study Improved antitumor activity of cisplatin combined with Ganoderma lucidu…	Mushroom	Preclinical	Emerging	7	4 trials View evidence Registry trials NCT06429514 — Study on the Mechanism of Ganoderma Lucidum Spore Powder in the Treatment of Depression (COMPLETED) NA NCT02238587 — The Effect of Ganoderma on Patients With Head-and-neck Cancer (UNKNOWN) NA NCT06979180 — A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (RECRUITING) NA NCT07524777 — Ganoderma Spores Modulate the Gut-Brain Axis (RECRUITING) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Saffron Natural product Animal Study Crocetin supplementation in the MCA mice also showed protection against… Animal Study Crocin induces autophagic cell death and inhibits cell invasion of cerv… Animal Study Synergistic effects of exosomal crocin or curcumin compounds and HPV L1…	Botanical	Preclinical	Emerging	7	1 trials View evidence Registry trials NCT02458001 — Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer (UNKNOWN) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Echinacea Natural product Human Study Echinacea angustifolia and Echinacea purpurea supplementation combined…	Botanical	Phase II	Emerging	7	2 trials View evidence Registry trials NCT01674374 — Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (WITHDRAWN) PHASE2 NCT03959410 — Impact of HPV on a Cohort of Southern Italian Women: Epidemiological, Clinical, Morphological and Microbiological Features (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Multivitamin Natural product Meta Analysis Dietary supplements reduce the risk of cervical intraepithelial neoplas… Human Study A case-control nutrigenomic study on the synergistic activity of folate… Human Study Echinacea angustifolia and Echinacea purpurea supplementation combined…	Nutraceutical	Phase III	Emerging	7	6 trials View evidence Registry trials NCT01265849 — Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity (COMPLETED) PHASE3 NCT05240911 — Individual Dosing of Levothyroxine After Thyroidectomy (UNKNOWN) NA NCT03531190 — Pre- and Postoperative Nutrition in Head and Neck Cancer Patients (COMPLETED) NA NCT00210470 — A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer (COMPLETED) PHASE2 NCT02609386 — IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity (COMPLETED) PHASE2 NCT03267680 — IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Ginkgo Biloba Natural product Animal Study, In Vitro Study Anti-cervical cancer activity of secondary metabolites of endophytic fu…	Botanical	Preclinical	Emerging	2	—	GreenMedInfo	GreenMedInfo
Baicalein Natural product Animal Study, In Vitro Study Baicalein enhances cisplatin sensitivity in cervical cancer cells by pr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Chrysin Natural product Animal Study, In Vitro Study Chrysin induces cell death and inhibits migration and invasion in squam…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Flavonoids Natural product Animal Study, In Vitro Study Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypo… Animal Study, In Vitro Study Engeletin suppresses cervical carcinogenesis in vitro and in vivo by re… Animal Study Kushenol E inhibits autophagy and impairs lysosomal positioning via VCP…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Apigenin Natural product Animal Study Apigenin may act as a chemotherapeutic agent for cervical cancer treatm…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Polyphenols Natural product Animal Study, In Vitro Study Hispolon suppresses metastasis via autophagic degradation of cathepsin… In Vitro Study An olive leaf extract rich in polyphenols promotes apoptosis in cervica…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Elecampane Natural product In Vitro Study Alantolactone exhibits selective antitumor effects in HELA human cervic… In Vitro Study Alantolactone induces apoptosis of human cervical cancer cells. In Vitro Study Alantolactone inhibits cervical cancer progression by downregulating BM…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ellagic Acid Natural product Human Study Women treated with the ellagic acid complex were less likely to be diag…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cucurbitacin E Natural product Animal Study, In Vitro Study Bacopa monieri has great potential for development of anticancer treatm… Animal Study, In Vitro Study These results demonstrate the potential therapeutic efficacy of Cucurbi… In Vitro Study 23,24-dihydrocucurbitacin B may be novel method of treating cervical ca…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bee Venom Natural product Animal Study Bee venom and thymoquinone combination inhibits cancer cells by inducin…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Chaga Mushroom (Inonotus Obliquus) Natural product Animal Study, In Vitro Study Chaga mushroom and its compounds could be used as natural anticancer in…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Tetrahydrocurcumin Natural product Animal Study Combinational treatment effect of tetrahydrocurcumin and celecoxib on c… Animal Study Tetrahydrocurcumin demonstrated an inhibitory effect against tumor angi… Animal Study Tetrahydrocurcumin inhibited tumor growth and tumor progression in CaSk…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Genistein Natural product Animal Study Genistein exerts an immunomodulatory effect in a mouse model of Human P…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Ginsenosides Natural product In Vitro Study 20(S)-ginsenoside Rg3 promotes HeLa cell apoptosis by regulating autoph… In Vitro Study 20(s)-ginsenoside Rg3-loaded magnetic human serum albumin nanospheres a… In Vitro Study 20(S)-ginsenoside Rh2-induced apoptosis and protective autophagy in cer…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Walnut Natural product In Vitro Study Alpha-tetralonyl glucosides from the green walnut husks of Juglans mand…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fennel Natural product In Vitro Study An aqueous extract of sweet fennel had a chemosensitizing effect on cis… In Vitro Study Analysis and evaluation of the antimicrobial and anticancer activities…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Angelica Natural product In Vitro Study Angelica sinensis contains a novel polysaccharide which induces program… In Vitro Study Angelicin inhibits the malignant behaviours of human cervical cancer po…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Anthocyanins Natural product In Vitro Study Anthocyanins from Vitis coignetiae inhibit cancer invasion and epitheli…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Mangosteen Natural product Human Study Fermented mangosteen supplementation in the prevention of HPV-induced c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactoferrin Natural product Human In Vitro Lactoferrin-induced up-regulation of zeta (zeta) chain expression in pe…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Gambogic Acid Natural product Animal Study, In Vitro Study Gambogic acid Lysinate-induced cervical cancer SiHa cells apoptosis. Animal Study Gambogic acid inhibits Hsp90 and deregulates TNF-α/NF-κB in HeLa cells.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Luteolin Natural product Animal Study, In Vitro Study Synergistic combination of luteolin and asiatic acid on cervical cancer.	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Astragaloside Natural product Animal Study, In Vitro Study Astragaloside IV inhibits the invasion and metastasis of SiHa cervical…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Artemisinin Natural product Animal Study Dihydroartemisinin (DHA), the main active metabolite of artemisinin der…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Prickly Pear Cactus Natural product Animal Study, In Vitro Study Eastern prickly pear extract may be a promising candidate for treating…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Indole-3-Carbinol Natural product Transgenic Animal Study Indole-3 carbinol prevents human papilloma virus induced cervical cance… Animal Study Indole-3-carbinol prevents the loss of the tumor suppressor gene PTEN i…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Spinach Natural product Animal Study, In Vitro Study Inhibitory effect on replicative DNA polymerases, human cancer cell pro… In Vitro Study A novel composite hydrogel initiated by Spinacia oleracea L. extract on…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Sage Natural product Animal Study, In Vitro Study Sage, Salvia officinalis L., constituents, hepatoprotective activity, a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Solanum Nigrum (Black Nightshade) Natural product Animal Study Solanum nigrum exhibits anticancer activity against cervical cancer in… Animal Study Solanum nigrum selectively inhibits human cervical cancer cells and cer… In Vitro Study A natural glucan from black bean inhibits cancer cell proliferation.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carotenoids Natural product Animal Study Synergistic effects of exosomal crocin or curcumin compounds and HPV L1…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Demethoxycurcumin Natural product Animal Study These effects and findings might provide evidence for investigating the…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
6-Shogaol Natural product In Vitro Study 6-shogaol as a novel thioredoxin reductase inhibitor induces oxidative-… In Vitro Study 6-Shogaol from ginger shows anti-tumor effect in cervical carcinoma via…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Shallot Natural product In Vitro Study A. hirtifolium might be a candidate for tumor suppression.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Adlay Natural product In Vitro Study Adlay seed ethanolic extract fractions and subfractions induce cell cyc… In Vitro Study Adlay sprout extract induces cell cycle arrest and apoptosis in human c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Emodin Natural product In Vitro Study Aloe-emodin induces mitochondrial dysfunction and pyroptosis by activat…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Dandelion Natural product Anticancer Effects of Taraxacum via Cell Cycle Arrest, Necrosis, Apopto…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rutin Natural product Bioactivities of Alchemilla alpina L. Extract on Women's Reproductive a… Anticancer potential of mangrove derived metabolites: cytotoxicity and… In vitro Evaluation of Anti-Cancer Potential of Different Solvent Extra…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Seaweed: Brown Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Kaempferol Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Medicinal Mushrooms Natural product Exploring the Bioactive Mycocompounds (Fungal Compounds) of Selected Me… Antiviral, Cytotoxic, and Antioxidant Activities of Three Edible Agaric… The anticancer effect of extract of medicinal mushroom Sanghuangprous v…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Mushrooms: All Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Betulinic Acid Natural product Synthesis and anticancer evaluation of new lupane triterpenoid derivati… Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER str… Exploring the Phytochemical Profile and Biological Activities of Clerod…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Salvia Miltiorrhiza Natural product Animal Study, In Vitro Study Sage, Salvia officinalis L., constituents, hepatoprotective activity, a…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carvacrol Natural product Targeting the interplay between human papillomavirus oncoproteins and h… Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with T… Oliveria decumbens Vent. (Apiaceae): Biological screening and chemical…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Catechin Natural product Results of a phase II randomized, double-blind, placebo-controlled tria…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Vitamin a Natural product Meta Analysis Dietary supplements reduce the risk of cervical intraepithelial neoplas… Meta Analysis Review: there is a consistently strong inverse correlations with solar… Human Study A case-control nutrigenomic study on the synergistic activity of folate…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Agaricus Blazei Natural product Human Study Agaricus blazei increases natural killer cell activity and quality of l…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fermented Foods and Beverages Natural product Human Study Fermented mangosteen supplementation in the prevention of HPV-induced c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Riboflavin (Vitamin B-2) Natural product Human Study Folate, riboflavin, thiamin and vitamin b12 protect against premalignan… Human Study A case-control nutrigenomic study on the synergistic activity of folate… Human Study Higher serum concentrations of folate and vitamin B12 are significantly…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Thiamine (B-1) Natural product Human Study Folate, riboflavin, thiamin and vitamin b12 protect against premalignan…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Folate: Dietary Natural product Human Study Higher serum concentrations of folate and vitamin B12 are significantly… Meta Analysis Deficiency of serum folate level was associated with the increased risk… Meta Analysis Dietary supplements reduce the risk of cervical intraepithelial neoplas…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Magnolol Natural product Human Study Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervica…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Alpha-Carotene Natural product Human Study These findings indicated that antioxidant vitamins might be beneficial… In Vitro Study Alpha-tetralonyl glucosides from the green walnut husks of Juglans mand…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Graviola Natural product Human Study Women treated with the ellagic acid complex were less likely to be diag…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Nigella Sativa (Aka Black Seed) Natural product Human In Vitro A Nigella sativa extract showed a 88.3% inhibition of proliferation of… In Vitro Study A natural glucan from black bean inhibits cancer cell proliferation. In Vitro Study An extract of black raspberries demonstrated significant growth inhibit…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Amla Fruit Natural product Human In Vitro An extract of Amla fruit inhibited human papillomavirus viral oncogenes…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network